<PAGE>   1
                                                                   EXHIBIT 10.15

*CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC
INFORMATION HAS BEEN FILED SEPARATELY WITH THE SEC. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.


LICENSE AND SUPPLY AGREEMENT entered into as of the 4th day of February 2000.



BETWEEN:    ARIDIA CORP., a corporation incorporated under the laws of the
            Province of Nova Scotia (hereinafter the "Corporation")





AND:        INFECTIO DIAGNOSTIC (I.D.I.) INC., a corporation incorporated under
            the laws of the Province of Quebec (hereinafter "IDI")




WHEREAS, IDI has expertise and know-how relating to certain nucleic acid
sequences for identification and diagnosis of certain human infectious disease
parameters as hereinafter described;

WHEREAS, Cepheid has granted to the Corporation an exclusive license to make,
use, offer to sell and sell its systems, subsystems and consumables (such as
disposable reaction tube), in combination with IDI proprietary technology for
diagnosing human disease parameters;

WHEREAS, IDI and the Corporation desire to enter into an agreement whereby JV
Products will be developed and commercialized with nucleic acid sequences from
IDI for use with devices and systems from Cepheid;

WHEREAS IDI, Cepheid and the Corporation have entered into a Joint Technology
and Collaboration Agreement dated February 4, 2000; and

WHEREAS IDI, Cepheid and the Corporation have entered into a Shareholders
Agreement dated February 4, 2000.





NOW THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth and other good and valuable consideration, the parties
hereby agree as follows:


<PAGE>   2
                                      -2-


                                    ARTICLE 1

                                   DEFINITIONS



As used in this agreement:

1.1   "AFFILIATE(s)" shall mean any corporation or other business entity
      controlled by or in common control of a party. "Control" as used herein
      means ownership directly or through one or more Affiliates, of fifty
      percent (50%) or more of the shares of the share capital entitled to vote
      for the election of directors, in the case of any corporation, or fifty
      percent (50%) or more of the equity interests in the case of any other
      type of legal entity, status as a general partner in any partnership, or
      any other arrangement whereby a party controls or has the right to control
      the board of directors or equivalent governing body of a corporation or
      other entity.

1.2   "CEPHEID" shall include all of the divisions, subsidiaries and Affiliates
      of Cepheid.

1.3   "CEPHEID INTELLECTUAL PROPERTY" shall mean all technology rights and
      patents rights (a) owned by Cepheid, existing as of the date hereof or
      developed subsequent to the date hereof and (b) relating to systems,
      subsystems and consumables for diagnosing human disease parameters
      including without limitations the patents and patents applications listed
      and described on Appendix A hereto. The Cepheid Intellectual Property
      shall also include any improvements, refinements, updates, discoveries or
      inventions related to Cepheid Intellectual Property and intellectual
      property developed by Cepheid in the course of the Collaboration Program
      as defined in the Collaboration Agreement.

1.4   "COLLABORATION AGREEMENT" shall mean the Joint Technology and
      Collaboration Agreement between the Corporation, IDI and Cepheid dated
      February 4, 2000;

1.5   "COST" shall mean [to be provided by the parties and shall take into
      account adjustment mechanisms]

1.6   "FIELD" shall mean the rapid diagnosis of human infectious diseases
      including but not limited to bacteria, fungi, antibiotic resistance and
      related disorders with systems integrating both IDI Intellectual Property
      and Cepheid Intellectual Property.

1.7   "IDI" shall include all of the divisions, subsidiaries and Affiliates of
      IDI.

1.8   "IDI INTELLECTUAL PROPERTY" shall mean all technology rights and patent
      rights (a) owned by IDI, existing as of the date hereof or developed
      subsequent to the date hereof and (b) relating to nucleic acid sequences
      useful for the identification and/or diagnosis of human infectious disease
      parameters, including, without limitation, the patents and patent
      applications listed and described on Appendix B hereto. The IDI
      Intellectual Property shall also include any improvements, refinements,
      updates, discoveries or inventions related to IDI Intellectual Property
      and intellectual property developed by IDI


<PAGE>   3

                                      -3-


      in the course of the Collaboration Program as defined in the Collaboration
      Agreement.

1.9   "IDI PRODUCTS" shall mean any products developed by IDI including but not
      limited to reagents or other assay materials to be incorporated in the
      Products.

1.10  "JV PRODUCTS" shall mean any of the Corporation Products integrating
      Cepheid Intellectual Property and IDI Intellectual Property.

1.11  "SHAREHOLDERS AGREEMENT" shall mean the Shareholders Agreement between
      IDI, Cepheid and the Corporation dated February 4, 2000, and any addenda
      and amendments of said agreement.

1.12  "TERRITORY" shall mean all of the countries in the world, including their
      respecting territories and possessions.

1.13  "TRANSFER PRICE" shall mean with respect to any IDI Product the price at
      which IDI will sell IDI Product to the Corporation as provided in Article
      3 hereof.


                                    ARTICLE 2

                         LICENSE AND TECHNOLOGY TRANSFER



2.1   LICENSE GRANT

      (a)   IDI hereby grants to the Corporation a fully paid-up, royalty-free,
            exclusive right and license in the Territory, with the right to
            grant sublicenses, in and to all IDI Intellectual Property and IDI
            Products to make, use, offer to sell and sell JV Products in the
            Field.

      (b)   If the Corporation grants a sublicense to a third party, the
            Corporation guarantees that such sublicense shall be in conformity
            with the terms and conditions of this Agreement and the Corporation
            shall not be relieved of its obligations pursuant to this Agreement
            as a result of such sublicense.

2.2   LIMITED RIGHTS

      Notwithstanding Section 2.1, the Corporation and Cepheid acknowledge and
      covenant that IDI can make, have made, use, offer for sale, and sell
      outside the Field in the Territory, directly or indirectly, IDI
      Intellectual Property and IDI Products for use with technology other than
      Cepheid Intellectual Property.

2.3   IDI WARRANTY

      To the best knowledge of IDI, IDI Intellectual Property and IDI Products
      do not infringe patents of third party.


<PAGE>   4
                                      -4-

                                    ARTICLE 3

                         SUPPLY AND USE OF IDI PRODUCTS



3.1   EXCLUSIVE PURCHASE

      The Corporation shall exclusively purchase IDI Products required for the
      manufacturing and sale of the Product from IDI and shall not use any third
      party product or technology other than IDI Products and IDI Intellectual
      Property for the manufacture and sale of JV Products except for Cepheid
      Intellectual Property.

3.2   PRODUCTION

      IDI declares that it is and shall be in a position to produce or cause to
      be produced IDI Products in a quantity necessary to meet the Corporation's
      reasonable projected sales forecast projections with reserves to include
      back-up supplies in the event such may be required.

3.3   TRANSFER PRICE

      The Transfer Prices at which IDI shall sell IDI Products to the
      Corporation shall be equal to the Cost of IDI Products plus [**]. Transfer
      pricing formulas will be periodically reviewed and adjusted as necessary
      upon agreement by both IDI and Cepheid to ensure their equitable sharing
      of revenues and profits generated by the Corporation.

3.4   TITLE TO IDI PRODUCTS

      To secure the payment of all amounts due hereunder and the observance and
      performance of all the terms, provisions, agreements and covenants of this
      Agreement, IDI reserves ownership of all IDI Products sold to the
      Corporation under the terms of this Agreement until the earlier of the
      dates on which the Corporation shall have (i) resold such IDI Products to
      a customer or (ii) made payment in full to IDI of all amounts due
      hereunder. Such reservation of ownership shall operate to the maximum
      extent permitted under the laws of the country in which the respective IDI
      Product is physically located, and the Corporation shall comply with all
      formalities required to give effect thereto.

3.5   FORECASTS

      For the purposes of Section 3.1, the Corporation shall provide IDI on a
      calendar quarterly basis with an updated two year forecast in order to
      enable IDI to develop realistic production requirements of IDI Products
      for future periods.

3.6   DELAY IN SUPPLY

      In the event that IDI would encounter circumstances out of its control
      where the supply of the IDI Products could not be provided to the
      Corporation, IDI shall so advise the Corporation, in the best of delays,
      and in such a case the parties shall attempt to find alternatives to
      supply the required IDI Products to the Corporation during the period in
      question.

<PAGE>   5
                                      -5-


3.7   TRANSPORTATION

      All IDI Products to be supplied by IDI to the Corporation shall be
      delivered to the Corporation F.O.B. Quebec, at the premises of the
      Corporation. Subject to the following, the parties agree that the term
      "F.O.B." shall be interpreted in accordance with the Incoterms 2000.
      Without limiting the generality of the foregoing, IDI Products shall be at
      the Corporation's sole risk and responsibility as of the moment that IDI
      Products have been placed on board the carrier specified by the
      Corporation.

3.8   EXPORT/IMPORT LICENSE

      Notwithstanding any provisions to the contrary, the obtainment of any and
      all export and/or import licenses as well as any and all required
      governmental consents are the sole responsibility of the Corporation, IDI
      declaring, however that it shall collaborate with the Corporation in this
      regard.




                                    ARTICLE 4

                                  INFRINGEMENT



4.1   INFRINGEMENT

      (a)   Each party shall promptly report in writing to the other party
            during the term of this Agreement any known infringement or
            suspected infringement of any Product, IDI Intellectual Property or
            IDI Products by a third party of which it becomes aware, and shall
            provide the other party with all available evidence supporting said
            infringement or suspected infringement.

      (b)   Except as provided in paragraph (d), the Corporation shall have the
            right to initiate an infringement or other appropriate suit against
            any third party who at any time has infringed, or is suspected of
            infringing, any Product, IDI Intellectual Property or IDI Products.
            The Corporation shall give IDI sufficient advance notice of its
            intent to file said suit and the reasons therefor, and shall provide
            IDI with an opportunity to make suggestions and comments regarding
            such suit. The Corporation shall keep IDI properly informed, and
            shall from time to time consult with IDI, regarding the status of
            any such suit.

      (c)   The Corporation shall have the sole and exclusive right to select
            counsel for any suit referred to in paragraph (b) and shall pay all
            expenses of the suit, including without limitation attorney's fees
            and court costs. If necessary, IDI shall join as a party to the suit
            but shall be under no obligation to participate except to the extent
            that such participation is required as the result of being a named
            party to the suit. IDI shall offer reasonable assistance to the
            Corporation in connection therewith at no charge to the Corporation
            except for reimbursement of reasonable out-of-pocket expenses (not
            including
<PAGE>   6
                                      -6-

            salaries of IDI personnel) incurred in rendering such assistance.
            IDI shall have the right to participate and be represented in any
            such suit by its own counsel at its own expense. The Corporation
            shall not settle any such suit involving rights of IDI without
            obtaining the prior written consent of IDI, which consent shall not
            be unreasonably.

      (d)   In the event that the Corporation elects not to initiate an
            infringement or other appropriate suit pursuant to paragraph (b),
            the Corporation shall promptly advise IDI of its intent not to
            initiate such suit, and IDI shall have the right, at the expense of
            IDI, of initiating an infringement or other appropriate suit against
            any third party who at any time has infringed, or is suspected of
            infringing, any Product, IDI Intellectual Property or IDI Products.
            In exercising its rights pursuant to this paragraph (d), IDI shall
            have the sole and exclusive right to select counsel and shall pay
            all expenses of the suit, including without limitation, attorney's
            fees and court costs, and shall be entitled to receive and retain
            any damages, royalties, settlement fees or other consideration. If
            necessary, the Corporation shall join as a party to the suit but
            shall be under no obligation to participate except to the extent
            that such participation is required as a result of being a named
            party of the suit. At IDI's request, the Corporation shall offer
            reasonable assistance to IDI at no charge to IDI except for
            reimbursement of reasonable out-of-pocket expenses (not including
            salaries of the Corporation personnel) incurred in rendering such
            assistance. The Corporation shall have the right to participate and
            be represented in any such suit by its own counsel at its own
            expense.

4.2   CLAIMED INFRINGEMENT

      Notwithstanding anything to the contrary in this Agreement, in the event
      that any action, suit or proceeding is brought against IDI or the
      Corporation, licensee or sublicensee of the Corporation alleging the
      infringement of the intellectual property rights of a third party by
      reason of the manufacture, use, sale or offer for sale of IDI Products,
      IDI Intellectual Property or JV Products by the Corporation, the
      Corporation will have the obligation to defend itself and IDI in such
      action, suit or proceeding at the Corporation's expense. IDI shall have
      the right to separate counsel at its own expense in any such action or
      proceeding. The parties will cooperate with each other in the defense of
      any such suit, action or proceeding. The parties will give each other
      prompt written notice of the commencement of any such suit, action or
      proceeding or claim or infringement and will furnish each other a copy of
      each communication relating to the alleged infringement, but the failure
      to do so shall not affect the Corporation's obligations under this Article
      and under Article 5 except to the extent the Corporation is actually
      damaged thereby. The Corporation shall not compromise, litigate, settle or
      otherwise dispose of any such suit, action or proceeding which involves
      the use of IDI Product or IDI Intellectual Property without IDI's advice
      and prior written consent, provided that IDI shall not unreasonably
      withhold its consent to any settlement which will provide an unconditional
      release of IDI.

<PAGE>   7
                                      -7-


4.3   LIMITED LIABILITY

      Notwithstanding anything else in this Agreement or otherwise, neither IDI
      nor the Corporation will be liable with respect to any subject matter of
      this Agreement under any contract, negligence, strict liability or other
      legal or equitable theory for any indirect, incidental, consequential or
      punitive damages or lost profits.

4.4   WARRANTY DISCLAIMER

      The Corporation agrees that there does not exist any warranty, guarantee,
      declaration or condition, express or implied, made by IDI, including
      implicit warranties as to merchantability, market quality, commercial
      value and fitness for any particular purpose whatsoever relative to IDI
      Intellectual Property or IDI Products or to the incorporation of IDI
      Products in the JV Products.



                                    ARTICLE 5

                                 INDEMNIFICATION


      The Corporation shall indemnify, defend and hold harmless IDI and its and
      their respective directors, officers, employees, and agents and their
      respective successors, heirs and assigns (the "IDI Indemnitees"), against
      any liability, damage, loss or expense (including reasonable attorneys'
      fees and expenses of litigation) incurred by or imposed upon the IDI
      Indemnitees, or any of them, in connection with any claims, suits,
      actions, demands or judgments of third parties, including without
      limitation, personal injury and product liability matters (except in cases
      where such claims, suits, actions, demands or judgments result from
      willful misconduct, gross negligence or material breach of this Agreement
      on the part of IDI Indemnitees) arising out of the development, testing,
      production, manufacture, promotion, import, sale or use by any person of
      any JV Products, IDI Products or IDI Intellectual Property manufactured or
      sold by the Corporation or by a licensee, sublicensee, distributor or
      agent of the Corporation. The Corporation shall have no obligation under
      this Article 5 with respect to incidental, indirect, or consequential
      damages or lost profits of IDI.


                                    ARTICLE 6

                       CONFIDENTIALITY AND NON-DISCLOSURE



      The parties agree that the Confidentiality provisions contained in the
      Shareholders Agreement apply to this Agreement with the necessary changes
      having been made.



<PAGE>   8
                                      -8-

                                    ARTICLE 7

                              TERM AND TERMINATION



7.1   TERM AND TERMINATION

      This Agreement shall continue in full force and effect until the
      expiration of the 6 month period following receipt by IDI or Cepheid of a
      notice of winding up sent pursuant to Article 4 of the Shareholders
      Agreement.

7.2   SURVIVAL OF OBLIGATIONS

      Articles 4, 5 and 6 of this Agreement shall survive its termination.

7.3   RETURN OF IDI PRODUCTS

      IDI shall have the right at its option to repurchase all or any part of
      the inventories of IDI Products in the Corporation's possession as of the
      termination of this Agreement at IDI's invoice price to the Corporation
      for such IDI Products less any appropriate amount for excessive wear and
      tear. IDI shall exercise its option by notifying the Corporation in
      writing no later than 30 days after the effective termination date.



                                    ARTICLE 8

                                    DISPUTES



8.1   NEGOTIATION AND MEDIATION

      If a dispute arises out of or relates to this Agreement or its breach (the
      "Matter"), the parties agree to resolve the Matter as follows:

      (a)   A party shall submit written notice of the Matter to the other
            parties and request negotiation.

      (b)   The parties shall attempt in good faith to resolve any Matter
            arising out of or relating to this Agreement promptly by negotiation
            between representatives which the parties may appoint, and (c) If
            the Matter has not been resolved within 60 days of a party's request
            for negotiation, either party may request that the Matter be
            submitted to a sole mediator selected by the parties for a mandatory
            1 day mediation;

8.2   ARBITRATION

      If the Matter has not been resolved by such mediation, either party may
      submit the Matter for binding arbitration, to a sole arbitrator in
      accordance with the Rules of Conciliation and Arbitration of the
      International Chamber of Commerce as in effect on the date of commencement
      of such arbitration, (the "ICC Rules") if the Corporation initiates the
      arbitration and pursuant to the Rules of the American Arbitration
      Association as in effect on the date of


<PAGE>   9
                                      -9-


      commencement of such arbitration if IDI initiates the arbitration (the
      "AAA Rules"), except where such ICC Rules or AAA Rules, as the case may
      be, conflict with the provisions of Article 8 in which event the
      provisions of this Article 8 shall prevail.

8.3   APPOINTMENT OF ARBITRATOR

      If the parties fail to agree on the appointment of the sole arbitrator
      within 20 days after one party has served the other party, a written
      notice to concur in the appointment of the single arbitrator nominated by
      the serving party, the sole arbitrator shall be appointed in accordance
      with the ICC Rules or AAA Rules, as the case may be. The sole arbitrator
      shall be a member of the Quebec Bar if the ICC Rules apply or the
      California Bar if the AAA Rules apply, with at least 10 years of
      experience in corporate commercial or intellectual property law. The
      arbitrator shall render any final award within 20 days following the
      completion of evidence and arguments on the Matter.

8.4   ADMISSIBILITY OF EVIDENCE IN OTHER PROCEEDINGS

      The parties shall not be entitled to rely on or introduce as evidence
      before any arbitral proceedings whether or not such proceedings relate to
      the Matter that is the subject of the negotiations:

      (a)   Views expressed or suggestions made by another party in respect of a
            possible settlement of the Matter;

      (b)   Admissions or proposals made by another party in the course of
            negotiations; or

      (c)   The fact that the other party had indicated his willingness to
            accept a proposal for settlement made by another party.

8.5   LOCATION

      The mediation and arbitration shall be held in Montreal, Quebec if the
      Corporation initiates the arbitration and in San Francisco, California if
      IDI initiates the arbitration. The parties, their representatives, the
      mediator and the arbitrator shall hold the existence, contend and results
      or any negotiation, mediation or arbitration in confidence unless
      disclosure is required by law or regulation, and in such case the parties
      shall take reasonable precautions to only disclose what is required by law
      or governmental regulation. All proceedings and all pleadings shall be in
      English.

8.6   AWARD

      Any award of the Arbitration shall be final and binding on the parties and
      shall be enforceable in any court having jurisdiction over the party from
      whom enforcement is requested.


<PAGE>   10
                                      -10-


                                    ARTICLE 9

                                     NOTICES



        Any notice, request, instruction or other document to be given hereunder
        shall be deemed validly given if in writing, and delivered personally,
        sent by overnight courier, or sent by certified mail, postage prepaid,
        return receipt requested, as follows:


        If to IDI:
        ---------

        Infectio Diagnostic (I.D.I.), Inc.
        2050 Rene Levesque Blvd. West
        Ste-Foy, Quebec, Canada G1V 2K8
        Attn:  Dr. Pierre Coulombe
        Facsimile: (418) 681-5254

        and if to the Corporation:
        -------------------------

        Aridia Corp.
        2050 Rene Levesque Blvd. West
        Ste-Foy, Quebec, Canada G1V 2K8
        Attn:  Dr. Pierre Coulombe
        Facsimile: (418) 681-5254

        And copy to:  Thomas L. Gutshall
        Facsimile: (408) 541-4192

        and copy to Cepheid:
        -------------------

        Cepheid
        1190 Borregas Avenue
        Sunnyvale, CA, 94089-1302
        Attn:  Thomas L. Gutshall
        Facsimile: (408) 541-4192


        Alternatively, notices and other communications may be sent by facsimile
        transmission with a confirmation copy sent by one of the forms of
        delivery set forth above. All notices and other communications shall be
        deemed delivered on the date of actual receipt.

<PAGE>   11
                                      -11-


                                   ARTICLE 10

                                  MISCELLANEOUS



10.1  ENTIRE AGREEMENT

      This Agreement along with the Collaboration Agreement, the Shareholders
      Agreement and the License and Supply Agreement between Cepheid and the
      Corporation constitutes the entire understanding between the parties with
      respect to the subject matter hereof and supersedes and replaces all prior
      agreements, understandings, writings and discussions between the parties
      relating to said subject matter. Only a written instrument executed by the
      parties may amend this Agreement.

10.2  WAIVER

      The failure of either party at any time or times to require performance of
      any provision hereof shall in no manner affect its rights at a later time
      to enforce the same. No waiver by either party of any condition or term in
      any one or more instances shall be construed as a further or continuing
      waiver of such condition or term or any other condition or term.

10.3  SUCCESSORS AND ASSIGNS

      This Agreement shall be binding upon and inure to the benefit of and be
      enforceable by the parties hereto and their respective successors and
      assigns and IDI shall not assign this Agreement without the prior written
      consent of the Corporation which cannot be unreasonably withheld.

10.4  FORCE MAJEURE

      Any delays in or failure of performance by either party under this
      Agreement shall not be considered a breach of this Agreement if and to the
      extent caused by occurrences beyond the reasonable control of the party
      affected, including but not limited to acts of God; acts, regulations, or
      laws of any government; strikes or other considered acts of workers;
      fires; floods; explosions; riots; wars; rebellion; and sabotage; and any
      time for performance hereunder shall be extended by the actual time of
      delay caused by such occurrence.

10.5  SEVERABILITY

      If any provision(s) of this Agreement are or become invalid, or ruled
      illegal by any court of competent jurisdiction, or are deemed
      unenforceable under then current applicable law from time to time in
      effect during the term hereof, it is the intention of the parties that the
      remainder of this Agreement shall not be affected thereby. It is further
      the intention of the parties that in lieu of each such provision which is
      invalid, illegal, or unenforceable, there be substituted or added as part
      of this Agreement, a provision which shall be as similar as possible in
      economic and business objectives as intended by the parties to such
      invalid, illegal, or unenforceable provision, but which shall be valid,
      legal, and enforceable, and shall be mutually agreed by the parties.



<PAGE>   12
                                     -12-


10.6  HEADINGS

      The headings contained herein are for reference purposes only and shall
      not in any way affect the meaning of this Agreement.

10.7  COUNTERPARTS

      This Agreement may be executed in any number of counterparts, each of
      which shall be an original, but all of which together shall constitute one
      instrument.

10.8  NO AGENCY

      Nothing contained in this Agreement shall be deemed to create a
      partnership between the Corporation and IDI. Neither party shall be liable
      for the act of the other party unless the other party expressly authorizes
      such act in writing.

10.9  GOVERNING LAW

      This Agreement shall be governed by and construed in accordance with the
      laws of the Province of Quebec, without regard to the application of
      principles of conflicts of laws thereof.



      IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.


INFECTIO DIAGNOSTIC (I.D.I.) INC    ARIDIA CORP.



Per: /s/ DR. PIERRE COULOMBE                Per: /s/ DR. PIERRE COULOMBE
    ------------------------------              ----------------------------
        Dr. Pierre Coulombe                        Dr. Pierre Coulombe


                                            Per:   /s/ THOMAS L. GUTSHALL
                                                ----------------------------
                                                   Thomas L. Gutshall

Cepheid intervenes to declare that it has taken cognizance of this Agreement and
that it accepts to be bound by Sections 2.2, 3.3 and 7.1.


CEPHEID



Per:   /s/ THOMAS L. GUTSHALL
    -------------------------------
        Thomas L. Gutshall




<PAGE>   13
                                      -13-


                                   APPENDIX A

                         CEPHEID INTELLECTUAL PROPERTY
<PAGE>   14

                                   APPENDIX A

                      TO THE LICENSE AND SUPPLY AGREEMENT
           BETWEEN INFECTIO DIAGNOSTIC (I.D.I.) INC. AND ARIDIA CORP.

                     CEPHEID PATENT RIGHTS AND APPLICATIONS


I.    Reaction vessel for heat-exchanging chemical processes.


<TABLE>
<CAPTION>
                                PATENT
         COUNTRY                NUMBER              ISSUED
<S>                           <C>              <C>
        UNITED STATES         US 5,958,349     Sept. 28, 1999
</TABLE>


<PAGE>   15
                                      -14-


                                   APPENDIX B

                            IDI INTELLECTUAL PROPERTY




<PAGE>   16
                                   APPENDIX B

                       TO THE LICENSE AND SUPPLY AGREEMENT
           BETWEEN INFECTIO DIAGNOSTIC (I.D.I.) INC. AND ARIDIA CORP.

                       IDI PATENT RIGHTS AND APPLICATIONS


I.    Specific and universal probes and amplification primers to rapidly detect
      and identify common bacterial pathogens and antibiotic resistance genes
      from clinical specimens for routine diagnosis in microbiology
      laboratories.


<TABLE>
<CAPTION>

--------------------------------------------------------------------------------
      COUNTRY          APPLICATION       FILING DATE          STATUS
                         NUMBER
--------------------------------------------------------------------------------
<S>                     <C>            <C>                  <C>
AUSTRALIA               34 681/95       Sept 12, 1995        292494

BRAZIL                  08/304732       Sept 12, 1995        Pending

CANADA                  1529278         April 2, 1998        Pending

CHINA                   CN1161060A      Oct 1, 1997          Pending

UNITED STATES           US526840        Nov 4, 1996          6,001,564

EUROPE              95 931 109.3-2116                        Pending

INDIA                   2153CAL97                            Pending

JAPAN                   504973/98       May 19, 1998         Pending

MEXICO                  97/01847        June 18, 1997        Pending

NORWAY                  971111          Sept. 1, 1998        Pending

NEW ZEALAND             JP207909        August 12, 1998      292494

SINGAPORE               9701090-4       Sept. 12, 1995       9701090-4
--------------------------------------------------------------------------------
</TABLE>


<PAGE>   17

II.   Species-specific, genus-specific and universal DNA probes and
      amplification primers to rapidly detect and identify common bacterial and
      fungal pathogens and associated antibiotic resistance genes from clinical
      specimens for diagnosis in microbiology laboratories.


<TABLE>
<CAPTION>

--------------------------------------------------------------------------------
      COUNTRY          APPLICATION       FILING DATE          STATUS
                         NUMBER
--------------------------------------------------------------------------------
<S>                     <C>              <C>                  <C>
ARGENTINA              P970105357         Nov. 14, 1997         Pending

AUSTRALIA              48598/97           Nov. 14, 1997         Pending

BRAZIL                 PI 9713494-5       Nov. 14, 1997         Pending

CANADA                 5044400            July 22, 1999         Pending

CHINA                  97180194.0         Nov. 4, 1997          Pending


UNITED STATES          WO98/20157         Nov. 4, 1997          Pending

EUROPE                 97911094.7 - 2116                        Pending


INDIA                  2153CAL97          Nov. 13, 1997         Pending

JAPAN                                     May 6, 1999           Pending

MEXICO                 99-4119            May 3, 1999           Pending

NORWAY                 19991976           April 26, 1999        Pending

NEW ZEALAND            335548             June 4, 1999          Pending

SINGAPORE              9901915-0          Nov. 4, 1997          Pending
--------------------------------------------------------------------------------
</TABLE>


<PAGE>   18

III.  Highly conserved genes and their use to generate species-specific,
      genus-specific, family-specific, group-specific and universal nucleic acid
      probes and amplification primers to rapidly detect and identify bacterial,
      fungal and parasitical pathogens from clinical specimens for diagnosis.


<TABLE>
<CAPTION>

--------------------------------------------------------------------------------
      COUNTRY          APPLICATION       FILING DATE          STATUS
                         NUMBER
--------------------------------------------------------------------------------
<S>                   <C>               <C>                   <C>
CANADA                CAN 2,283,458     Sept. 28, 1999        Pending
--------------------------------------------------------------------------------
</TABLE>

<PAGE>   19


IV.   Specific and universal probes to rapidly detect and identify common
      bacteria form urinary or any other biological samples in the routine
      microbiology laboratory.



<TABLE>
<CAPTION>

--------------------------------------------------------------------------------
      COUNTRY          APPLICATION       FILING DATE          STATUS
                         NUMBER
--------------------------------------------------------------------------------
<S>                   <C>               <C>                 <C>
UNITED STATES         85-586-9001-2     Sept. 12, 1994      08/304,732

UNITED STATES S.N.    850586.90012      Sept. 11, 1995      08/526,840

--------------------------------------------------------------------------------
</TABLE>


<PAGE>   20

V.    Species-specific and universal DNA probes and amplification primers to
      rapidly detect and identify common bacterial pathogens and associated
      antibiotic resistance genes from clinical specimens for routine diagnosis
      in microbiology laboratories.


<TABLE>
<CAPTION>

--------------------------------------------------------------------------------
      COUNTRY          APPLICATION       FILING DATE          STATUS
                         NUMBER
--------------------------------------------------------------------------------
<S>                     <C>            <C>                  <C>
UNITED STATES          US 743,637        Nov. 4, 1996        5,994,066

--------------------------------------------------------------------------------
</TABLE>